Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PROVECTUS BIOPHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for PROVECTUS BIOPHARMACEUTICALS, INC.

PVCT

PROVECTUS BIOPHARMACEUTICALS, INC.

About PROVECTUS BIOPHARMACEUTICALS, INC.

Provectus Biopharmaceuticals is a clinical-stage biotech company developing immunotherapy medicines based on pharmaceutical-grade rose bengal sodium (RBS). Its pipeline includes drug candidates for oncology, dermatology, ophthalmology, and infectious diseases, utilizing various delivery methods. The company holds multiple patents, collaborates with academic institutions, and aims to advance treatments through clinical trials, regulatory approvals, and potential commercialization in global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PROVECTUS BIOPHARMACEUTICALS, INC.

1
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports $1.3 Million Net Loss in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports $5.5 Million Net Loss and Decreased Revenue for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports Significant Financial Losses and Liquidity Challenges in Latest 10-Q

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports Increased Net Losses and Declining Grant Revenue in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports Q1 2025 Financial Results with Increased Losses and Rising Grant Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports $4.76 Million Net Loss and Revenue Growth Amid Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PROVECTUS BIOPHARMACEUTICALS, INC. Provectus Biopharmaceuticals Reports Mixed Financial Results, Doubts Ability to Continue as Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments